5-Amino-1MQ Dosage, half-life & reference guide
Also known as 5-A-1MQ · 5Amino1MQ · 5-Amino-1-methylquinolinium
A small molecule (not a peptide) that blocks the NNMT enzyme in fat cells, which raises NAD+ and pushes fat cells toward burning energy. In obese mice it reduced weight and fat without cutting food intake.
- Studied range
- 50–100 mg
- How often
- Daily
- Half-life
- Unknown
- Evidence
- ●
●●Emerging - Route
- Oral
Studied in research — not a recommendation.
How it works.
NNMT (Nicotinamide N-methyltransferase) inhibitor that blocks NNMT activity in fat cells. In cultured fat cells it raises NAD+ and SAM levels; in obese mice it cut body weight and fat without reducing food intake, and with a reduced-calorie diet lean mass made up a larger share of body weight. No human data.
Commonly reported: Nothing to feel, though some describe easier fat loss alongside a deficit or a GLP-1. There are no human studies, and the mouse work used injections rather than oral doses.
Where 5-Amino-1MQ works.
Appetite & metabolism
In animals. In obese mice it cut body weight and fat without reducing food intake.
Energy & longevity
In the lab. In cultured fat cells it raises NAD+ and SAM levels.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
Day 1–28Animal
Quiet compound, slow signal
5-Amino-1MQ doesn't announce itself. Commonly reported: no appetite change, no energy spike, no obvious sensation. What mouse data shows is a slightly better body-composition response to the same diet, especially in a deficit, so give it the full month before judging.
The science
5-Amino-1-methylquinolinium is a selective NNMT (nicotinamide N-methyltransferase) inhibitor. In cultured fat cells, blocking NNMT raised NAD+ and SAM and reduced fat synthesis; this pushes fat cells toward burning energy (SIRT1 involvement is proposed, and fat oxidation wasn't measured). Neelakantan et al. 2018: obese mice injected three times daily lost about 5% of body weight over 11 days while controls gained about 1.4%, with food intake unchanged.
Sources- Neelakantan et al. (2018)
Updated Sep 2026
Day 28–84Animal
Recomp in a deficit
The rodent data's clearest signal is fat loss without eating less; paired with a diet, lean mass made up a larger share of body weight. If you're using this with a cut, this is the window to watch scale, waist and grip strength together.
The science
NNMT inhibition shifts fat-cell metabolism toward energy expenditure and away from storage. In a follow-up mouse study, adding the inhibitor to a reduced-calorie diet raised the lean-to-body-weight ratio compared with diet alone (Sampson 2021). Human data is essentially nonexistent — we're extrapolating.
Sources- Neelakantan et al. (2018)
- Sampson et al. (2021)
Updated Sep 2026
Any dayAnimal
What 5-Amino-1MQ is built on
Interesting mechanism, positive rodent data, zero completed human trials. Treat as an early-stage research compound you're testing on yourself. Small molecule, not a peptide — included because it's commonly tracked alongside metabolic peptide protocols.
The science
Developed originally as a tool compound to study NNMT biology. Rodent pharmacokinetics are only partly published, and human pharmacokinetics are not published. Research-use-only status in the US. Quality and purity of community-sourced material is an additional concern — verify your source.
Sources- Neelakantan et al. (2018)
- Sampson et al. (2021)
Updated Sep 2026
With Semaglutide, Tirzepatide and RetatrutideCommunity
Layered onto a GLP-1 cut
Common community pattern: 5-Amino-1MQ layered onto an ongoing GLP-1 protocol. The GLP-1 drives the calorie deficit while 5-Amino-1MQ helps protect lean mass from the fat-cell side (a mouse finding). Commonly reported: some find recomposition a bit easier; others notice no change.
The science
GLP-1 agonists drive weight loss primarily via appetite reduction; 5-Amino-1MQ acts peripherally at fat cells on NNMT/NAD+ signaling (SIRT1 involvement is proposed). By mechanism, additive rather than synergistic. No head-to-head or combination trial exists.
Sources- Neelakantan et al. (2018)
Updated Sep 2026
After week 8
Day 84–168Animal
Cycle decision point
Most community use lands in the 8–12 week range, but honestly: no chronic human data exists, so any endpoint is arbitrary. Treat this as a reassessment checkpoint — did body composition shift, did metabolic markers move? A 2–3 month break before a second run is the conservative default.
The science
No chronic human dosing data exists. NNMT has different roles in fat, liver and brain (Roberti 2021 review), so long-term blocking could have different effects in each, one argument for cycling; the cycle length itself is community convention.
Sources- Roberti et al. (2021)
Updated Sep 2026
Day 1 is the day you start it.
A typical run.
Run notes
- Cycle
- Very limited data. Some run 8–12 weeks then cycle off. Preclinical compound — approach conservatively.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- Oral daily. Timing not well established.
- Route
- Oral
- Stacks
- NMN, Semaglutide
Safety.
Common side effects
- Limited human data
- Generally well tolerated in early research
Goes with.
Questions people ask.
What is 5-Amino-1MQ?
A small molecule (not a peptide) that blocks the NNMT enzyme in fat cells, which raises NAD+ and pushes fat cells toward burning energy. In obese mice it reduced weight and fat without cutting food intake.
How is 5-Amino-1MQ dosed in research?
The research range for 5-Amino-1MQ is 50–100 mg, daily. Studied in research — not a recommendation.
How long does 5-Amino-1MQ last?
The half-life of 5-Amino-1MQ is unknown.
What do people report on 5-Amino-1MQ?
Commonly reported on 5-Amino-1MQ: nothing to feel, though some describe easier fat loss alongside a deficit or a GLP-1. There are no human studies, and the mouse work used injections rather than oral doses.
Is 5-Amino-1MQ safe?
The research basis for 5-Amino-1MQ is emerging: primarily preclinical / limited human data. Common side effects in the library: limited human data and generally well tolerated in early research.
What does 5-Amino-1MQ stack with?
Common stacks for 5-Amino-1MQ: NMN and Semaglutide.
Research.
Reference.
- Cadence
Daily
- Half-life
Unknown
- Research basis
●
●●EmergingPrimarily preclinical / limited human data
PepVault for iPhone
Track 5-Amino-1MQ in PepVault
Log every dose, with reminders on your schedule. 7 days free on the yearly plan for new subscribers.
Reviewed How we check the library